Stephens analyst Mason Carrico lowered the firm’s price target on Akoya Biosciences to $9 from $14 and keeps an Overweight rating on the shares. Akoya reported “solid” Q3 results that increased the firm’s confidence in the company’s ability to achieve its goal of holding OpEx flat going forward while continuing to grow the top line. However, the firm lowered its price to reflect a moderated FY24 revenue estimate and multiple contraction across the broader life science tools/genomics space.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AKYA:
- Akoya Biosciences sees FY23 revenue $95M-98M, consensus $96.74M
- Akoya Reports Record Revenue in the Third Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance
- Akoya Biosciences reports Q3 EPS (26c), consensus (37c)
- Akoya Biosciences to showcase spatial biology 2.0 solutions
- Akoya Biosciences to Showcase New Spatial Biology 2.0 Solutions and Spatial Phenotyping Data at SITC 2023
